Skip to content

Perioperative TEAS on long-term outcomes in patients undergoing cancer surgery: a single-center, prospective, randomized, controlled study

Perioperative TEAS on long-term outcomes in patients undergoing cancer surgery: a single-center, prospective, randomized, controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093204
Enrollment
Unknown
Registered
2024-11-29
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

TEAS group 1:Continuous transcutaneous electrical acupoint stimulation 30 minutes before and during the operation
TEAS group 2:Giving transcutaneous electrical acupoint stimulation 3 to 5 days after the surgery
Control group:None

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1)Laparoscopic radical resection of gastric, bowel, liver, lung, kidney, prostate cancer was performed under elective general anesthesia, and no metastatic lesions were found before operation; (2)ASA graded I-III grade, 18kg/m^2<BMI<= 31 kg/m^2, aged 18-75 years and no gender limitation; (3)No cognitive, communication disorders, mental disorders, able to communicate, understand and sign informed consent.

Exclusion criteria

Exclusion criteria: (1)There are surgical incisions or surgical scars, skin infections, nerve injuries in the local of the acupoint and the meridian, or a history of spinal surgery; (2)Participated in other clinical trials in the last four weeks; (3)Can't understand the NRS score, can't use the PCIA; (4)Having preoperative pain, central analgesics are being used or having opioid addiction, dependence; (5)Long-term use of hormone drugs and allergies; (6)People with liver and kidney problems(ALT, AST, BUN, Cr 1.5 above normal), K+>5.5mmol/L or K+<3.0mmol/L, preoperative Hb<7g/dl; (7)The researchers did not consider participants suitable for this trial.

Design outcomes

Primary

MeasureTime frame
The recurrence free survival ;

Secondary

MeasureTime frame
The CTC count;The Immune factor count;Complications 30 days after surgery;Overall survival time ;Postoperative NRS score;

Countries

China

Contacts

Public ContactWang Junlu; Pan Yuanyuan

The First Affiliated Hospital of Wenzhou Medical University

wangjunlu973@163.com+86 138 0668 9854

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026